| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
sBLA Submission example | sBLA | — | Subscribe to access the data. | Biologics | Nervous System | ||
sBLA Submission example | sBLA | — | Subscribe to access the data. | Biologics | Nervous System | ||
sBLA Submission example | sBLA | — | Subscribe to access the data. | Biologics | Nervous System |
Recent Updates
Recently added Catalysts
TG Therapeutics, Inc.$57.12
-1.94 (-3.28%)
B 66Pipeline Score Fair Value Pharma · Commercial
Market Cap
5.95 B
EPS
3.18
P/E Ratio
13.55 $
Value Trade
147.07 M
SEC Financials
Q1 2026Dilution Risk
Revenue
204.92 M
R&D Expenses
48.40 M
Operating CF
-17.89 M
Total Assets
1.53 B
Total Liabilities
945.71 M
Equity
583.13 M
D/E Ratio
12,345
-3.67 %
Week
6.55 %
1 Month
32.53 %
3 Month
27.86 %
6 Month
16.73 %
5 Year
-99.95 %
All Time
Cash Data
Cash Position
514.43 M
Monthly Burn
5.96 M
Runway
84 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
1.23 M
52 Week Range
25.28 - 44.65
% held by Insiders
7.47 %
% held by Institutions
69.22 %
Enterprise Value
6.19 B
Total Shares
153.09 M
Short %
20.48 %
Float Shares
147.28 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for TG Therapeutics, Inc.
510Total events
7Upcoming
131Tier-1 (high impact)
2006 – 2028Coverage
Upcoming catalysts 7
TBD
T2Oral Presentation
Final Phase 1 subcutaneous BRIUMVI data to be presented at future medical meeting
Event history 503
Jul 6, 2026
▲Trial InitiationBRIUMVIApprovedTrial
Initiation of Phase 2 trial evaluating BRIUMVI in treatment-resistant schizophrenia
treatment-resistant schizophreniasource ↗
Q3 2026
◆sNDA SubmissionBRIUMVIApprovedRegulatory Filing
Supplemental BLA submission targeted for consolidated dosing regimen
relapsing forms of multiple sclerosissource ↗
Jun 9, 2026
◆Oral PresentationPresentation
TG Therapeutics to participate in Goldman Sachs 47th Annual Healthcare Conference fireside chat
Jun 9, 2026
▲Topline ReadoutBRIUMVIApprovedClinical Data
Positive topline Phase 1 data for subcutaneous BRIUMVI in MG
myasthenia gravissource ↗
Jun 9, 2026
▲Trial InitiationBRIUMVIApprovedTrial
Initiation of Phase 2 trial evaluating BRIUMVI as maintenance therapy after efgartigimod induction
myasthenia gravissource ↗
Jun 3, 2026
◆Oral PresentationPresentation
TG Therapeutics to participate in Jefferies Global Healthcare Conference fireside chat
Jun 3, 2026
▲Topline ReadoutBRIUMVIApprovedClinical Data
Positive Phase 1 results for subcutaneous BRIUMVI
relapsing multiple sclerosissource ↗
Jun 3, 2026
▲Enrollment CompleteBRIUMVIApprovedTrial
Phase 3 subcutaneous BRIUMVI trial enrollment completed
relapsing multiple sclerosissource ↗
May 28, 2026
◆Oral PresentationBRIUMVIApprovedPresentation
Oral presentation of ENABLE Phase 4 study results on patient-reported outcomes
relapsing forms of multiple sclerosissource ↗
May 28, 2026
◆Poster PresentationBRIUMVIApprovedPresentation
Poster presentation on ublituximab infusion tolerability from ULTIMATE Phase 3 studies
relapsing forms of multiple sclerosissource ↗
May 27, 2026
▲Primary Endpoint MetBRIUMVIApprovedClinical Data
ENHANCE Phase 3 trial met primary endpoint of bioequivalence for consolidated single infusion regimen
relapsing forms of multiple sclerosissource ↗
May 6, 2026
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Business Update Conference Call
Drug Pipeline Intelligence
B66
Pipeline Score $5.0B
Pipeline ValueFair Value
Valuation Signal9
Drugs Scored0.8x
rNPV / MCap Top 92%
Small Cap (rank 74 of 912)
Percentile RankTG Therapeutics, Inc. holds a solid B-grade pipeline (66/100), with $7.7B risk-adjusted pipeline value, led by Ublituximab in Relapsing Multiple Sclerosis (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ublituximab Monoclonal antibody | Relapsing Multiple Sclerosis | Phase 3 | NCT07211633 | 68% | $4.9B | ACTIVE NOT_RECRUITING | 1,400 | FAST | C (49) | Dec 31, 2028 | MODERATE_RISK | LOW Jun 18, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BRIUMVI | myasthenia gravis | Phase 1 | 2026-06-09 | 82%; mean >4 point improvement; n=11; mean baseline MG-ADL of 8.24; mean baseline QMG score of 12.0; median time to MCID of 30 days; mean 4.6 point improvement in MG-ADL Read More | TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial Read More | |
BRIUMVI | myasthenia gravis | Phase 1 | 2026-06-09 | 82%; mean >4 point improvement; n=11; mean baseline MG-ADL of 8.24; mean baseline QMG score of 12.0; median time to MCID of 30 days; mean 4.6 point improvement in MG-ADL Read More | TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial Read More | |
BRIUMVI | myasthenia gravis | Phase 1 | 2026-06-09 | 82%; mean >4 point improvement; n=11; mean baseline MG-ADL of 8.24; mean baseline QMG score of 12.0; median time to MCID of 30 days; mean 4.6 point improvement in MG-ADL Read More | TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TGTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TGTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TGTXTG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
TG Therapeutics has initiated a Phase 2 clinical trial for BRIUMVI (ublituximab-xiiy) in adults with treatment-resistant schizophrenia. The study aims to evaluate the efficacy and safety of BRIUMVI in approximately 60 participants who have not responded adequately to standard antipsychotic treatments. The trial is based on emerging evidence suggesting a role for B-cell depletion in managing schizophrenia symptoms.
Read more →TGTX▲ +5.9%on this news· ran to +21% by day 3
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
TG Therapeutics announced positive topline results from a Phase 1 study of subcutaneous BRIUMVI in patients with myasthenia gravis, showing that 82% of participants achieved a Minimal Clinically Important Difference in their MG-ADL scores. The company is initiating a Phase 2 trial to evaluate BRIUMVI as a maintenance therapy after induction with efgartigimod. This trial aims to assess the efficacy of BRIUMVI in maintaining clinical responses in MG patients.
Read more →TGTX▲ +9.5%on this news
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
TG Therapeutics announced positive results from a Phase 1 trial for its subcutaneous formulation of BRIUMVI (ublituximab). The trial demonstrated good safety and tolerability, with pharmacokinetic data supporting a quarterly dosing regimen. The company anticipates that this formulation could become the first self-administered anti-CD20 therapy for multiple sclerosis, with Phase 3 results expected by early 2027.
Read more →TGTXTG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
TG Therapeutics, Inc. will participate in the Goldman Sachs 47th Annual Healthcare Conference from June 8-10, 2026. CEO Michael S. Weiss is scheduled for a fireside chat on June 9 at 2:00 PM ET. A live webcast will be available on the company's website, enhancing accessibility for investors.
Read more →TGTXTG Therapeutics to Participate in the Jefferies Global Healthcare Conference
TG Therapeutics will participate in the Jefferies Global Healthcare Conference from June 2-4, 2026. CEO Michael S. Weiss is scheduled to speak during a fireside chat on June 3 at 11:40 AM ET. The event will be accessible via a live webcast on the company's website. TG Therapeutics is known for its focus on treatments for B-cell diseases.
Read more →TGTXTG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
TG Therapeutics announced positive topline results from the Phase 3 ENHANCE trial, which evaluated a new single infusion regimen of BRIUMVI for treating relapsing forms of multiple sclerosis. The trial demonstrated bioequivalence between the new regimen and the existing two-infusion regimen, potentially streamlining patient treatment. A supplemental BLA filing is targeted for the second half of 2026.
Read more →TGTXTG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics announced data presentations for BRIUMVI at the 2026 Consortium of Multiple Sclerosis Centers annual meeting. The presentations will showcase findings from the ENABLE Phase 4 study, highlighting significant patient-reported outcomes and real-world data demonstrating effective disease control. The event will take place from May 27-29, 2026, in Charlotte, N.C.
Read more →TGTX▲ +16.3%on this news
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics reported strong financial results for Q1 2026, with total global revenue of approximately $205 million, driven by BRIUMVI's U.S. net revenue of about $195 million. The company raised its full-year revenue guidance for BRIUMVI to between $885 million and $900 million, reflecting strong market demand and new patient starts. Additionally, TG Therapeutics announced ongoing clinical trials and a robust pipeline for BRIUMVI and other therapies.
Read more →TGTXTG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
TG Therapeutics will host a conference call on May 6, 2026, at 8:30 AM ET to discuss its first quarter financial results and business outlook for the remainder of the year. CEO Michael S. Weiss will lead the call, which will also be available via live webcast. The company has FDA approval for its treatment BRIUMVI for multiple sclerosis.
Read more →TGTX▲ +5.6%on this news
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
TG Therapeutics announced the presentation of new data on BRIUMVI at the AAN 2026 annual meeting. The findings from the ENABLE and ENHANCE studies emphasize the drug's effectiveness and safety for treating relapsing multiple sclerosis (RMS). The company aims to provide insights into optimized dosing and continue expanding clinical data supporting BRIUMVI as a treatment option.
Read more →TGTXData Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
TG Therapeutics announced positive results from a pooled analysis of Phase 3 studies on BRIUMVI (ublituximab) for treating highly active relapsing multiple sclerosis. The data, published in Neurology and Therapy, demonstrated significant reductions in relapse rates and MRI activity compared to teriflunomide. The findings support the early use of BRIUMVI in patients at risk for rapid disease progression.
Read more →TGTXTG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics reported strong financial results for Q4 and full year 2025, with total revenues of $192.6 million and $616.3 million, respectively. The company raised its revenue guidance for 2026 to approximately $875-900 million, driven by the success of its BRIUMVI product. CEO Michael S. Weiss highlighted the company's momentum and focus on future clinical milestones.
Read more →TGTXTG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
TG Therapeutics will hold a conference call on February 26, 2026, to discuss its financial results for Q4 and the full year of 2025. CEO Michael S. Weiss will lead the call, which will also provide a business outlook for 2026. A live webcast will be available, and a recording will be accessible for 30 days post-call.
Read more →TGTXLong Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis
TG Therapeutics announced the publication of five-year data from the Phase 3 ULTIMATE I and II studies on BRIUMVI for relapsing multiple sclerosis. The results indicate a low annualized relapse rate of 0.020 and a consistent safety profile over the treatment period. The findings support the long-term efficacy of BRIUMVI, emphasizing its role as a valuable treatment option for patients with relapsing MS.
Read more →TGTXTG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
TG Therapeutics announced the presentation of data for BRIUMVI (ublituximab) at the ACTRIMS annual forum in San Diego. The presentations include updates from the ENABLE study and details on the ULTIMATE KIDS trials, focusing on the treatment of relapsing multiple sclerosis. The company aims to enhance clinical understanding and support the MS community with this data.
Read more →TGTXTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
TG Therapeutics has announced its presentation schedule for BRIUMVI (ublituximab) at the upcoming ACTRIMS annual forum. The presentations will cover various studies, including Phase 2 and Phase 3 trials focused on relapsing multiple sclerosis. BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, offering a new treatment option for patients with RMS. The data will be available online following the presentations.
Read more →TGTX▲ +6%on this news
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
TG Therapeutics announced preliminary revenue figures for BRIUMVI, projecting approximately $616 million for 2025 and $875-900 million for 2026. The company highlighted strong commercial performance and plans for expanded indications. CEO Michael S. Weiss expressed confidence in the product's growth potential, while also noting the importance of upcoming development milestones. However, the company acknowledged risks related to infusion reactions and infections.
Read more →TGTXTG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
TG Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. CEO Michael S. Weiss will lead the presentation, showcasing the company's advancements in B-cell disease treatments. A live webcast will be available, with a replay accessible post-event. The company has a notable FDA-approved treatment, BRIUMVI, for multiple sclerosis.
Read more →TGTXTG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
TG Therapeutics will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025. CEO Michael S. Weiss is scheduled for a fireside chat on December 2 at 12:30 PM ET. A live webcast will be available on the company's website, highlighting their focus on B-cell diseases and recent FDA approval for BRIUMVI.
Read more →TGTXTG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
TG Therapeutics has been recognized as the 27th fastest-growing company in North America by Deloitte, driven by significant revenues from its MS treatment, BRIUMVI. This achievement highlights the company's growth from 2021 to 2024 and underscores its commitment to advancing treatments for autoimmune diseases. CEO Michael S. Weiss expressed gratitude for the recognition, attributing it to the efforts of employees and healthcare providers.
Read more →TGTXTG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
TG Therapeutics, Inc. will participate in the TD Cowen Immunology & Inflammation Summit on November 12-13, 2025. CEO Michael S. Weiss is scheduled for a fireside chat on November 12 at 10:00 AM ET. The event will be available via live webcast on the company's website.
Read more →TGTXTG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics announced its Q3 2025 financial results, reporting total revenue of $161.7 million, with BRIUMVI U.S. net revenue at $152.9 million. The company raised its full-year revenue guidance for BRIUMVI to approximately $585 million, reflecting strong market demand. CEO Michael S. Weiss highlighted the company's focus on expanding patient awareness and advancing clinical trials.
Read more →TGTXTG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
TG Therapeutics, Inc. will host a conference call on November 3, 2025, to discuss its third-quarter financial results and business outlook. CEO Michael S. Weiss will lead the call, which will also be available via webcast. The company plans to release its financial results prior to the call.
Read more →TGTXTG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
TG Therapeutics has completed enrollment in the Phase 3 ENHANCE trial, which evaluates a new simplified dosing schedule for BRIUMVI in patients with relapsing forms of multiple sclerosis. The trial aims to determine if a consolidated Day 1 infusion can maintain the drug's efficacy compared to the current regimen. If successful, this new dosing could enhance patient convenience and be launched by 2027.
Read more →TGTXNew Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
TG Therapeutics announced new data from the ULTIMATE I & II Phase 3 trials, showing that 89.9% of patients with relapsing multiple sclerosis remained free from disability progression after six years of continuous treatment with BRIUMVI. The annualized relapse rate was notably low at 0.012. The safety profile remained consistent, with no new safety signals identified.
Read more →TGTXTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
TG Therapeutics announced its schedule for data presentations on BRIUMVI at the 2025 ECTRIMS annual meeting. The presentations will focus on the long-term efficacy and safety of BRIUMVI in treating relapsing forms of multiple sclerosis, along with updates from the ENHANCE study and real-world clinical experiences. The data will be available online after the presentations.
Read more →TGTXTG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
TG Therapeutics has initiated enrollment in a Phase 3 trial for subcutaneous BRIUMVI, an anti-CD20 monoclonal antibody for relapsing forms of multiple sclerosis. This trial aims to evaluate the safety and efficacy of subcutaneous administration compared to the currently approved intravenous method. If successful, BRIUMVI may provide patients with more treatment options and potentially gain FDA approval by 2028.
Read more →TGTXTG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
TG Therapeutics, Inc. announced that CEO Michael S. Weiss will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The fireside chat is scheduled for September 8 at 10:30am ET. A live webcast will be available on the company's website.
Read more →TGTX▲ +6.7%on this newsshared move
TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program
TG Therapeutics has successfully completed its $100 million share repurchase program, acquiring approximately 3.5 million shares. The Board of Directors has now authorized an additional $100 million for further share repurchases, reflecting confidence in the company's value and growth potential, particularly regarding its product BRIUMVI.
Read more →TGTXTG Therapeutics to Participate in the Cantor Global Healthcare Conference
TG Therapeutics, Inc. announced its participation in the Cantor Global Healthcare Conference, scheduled for September 3-5, 2025, in New York. CEO Michael S. Weiss will engage in a fireside chat on September 3 at 10:20 AM ET. A live webcast of the event will be available on the company's website.
Read more →TGTX▼ -49.3%on this news
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results Second quarter 2023 BRIUMVI net sales of $16 million in the United States, representing 100% quarter over quarter growth; total n
TG Therapeutics announced its second quarter 2023 financial results, highlighting BRIUMVI's strong performance with $16 million in net sales, representing a 100% increase from the previous quarter. The medication, part of B-cell depletion therapy for multiple sclerosis, has received over 1,200 prescriptions and 80% payor coverage in the U.S. The recent agreement with Neuraxpharm for ex-U.S. commercialization is expected to enhance TG Therapeutics' financial position. Despite these successes, potential risks associated with infusion reactions and serious infections were acknowledged in the announcement.
Read more →TGTX▲ +23.4%on this news· ran to +41% by day 3
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results First quarter 2023 BRIUMVI net sales of $7.8 million Over 400 BRIUMVI prescriptions in the first partial quarter from 165+ healthc
TG Therapeutics reported its financial results for the first quarter of 2023, highlighting BRIUMVI's net sales of $7.8 million and over 400 prescriptions written within the initial launch period. The company noted positive payor coverage and encouraging feedback from healthcare providers and patients. Despite the optimistic outlook, the report also mentioned serious safety concerns associated with BRIUMVI, including infusion reactions and potential infections. TG Therapeutics maintains a hopeful trajectory for continued growth and acceptance of BRIUMVI in the multiple sclerosis treatment landscape.
Read more →TGTXTG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results Conference call to be held today, Tuesday
TG Therapeutics announced its fourth quarter and year-end 2022 financial results, highlighting the approval and commercial launch of BRIUMVI for relapsing forms of Multiple Sclerosis. CEO Michael S. Weiss expressed optimism about early feedback from the launch and emphasized their commitment to patient access to the treatment. However, the announcement also included concerns about potential serious side effects, including infusion reactions and the risk of infections related to BRIUMVI treatment.
Read more →TGTX▲ +22.9%on this news· ran to +40% by day 1
TG Therapeutics Announces FDA Approval of BRIUMVI (ublituximab-xiiy) BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered i
TG Therapeutics Announces FDA Approval of BRIUMVI (ublituximab-xiiy) BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion twice-a-year following the starting d
Read more →TGTX▲ +63.4%on this news· ran to +81% by day 1
TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results Conference call to be held today
TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results Conference call to be held today, November 10, 2022 at 8:30 AM ET New York, NY, (November 10, 2022) - TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the thi
Read more →TGTX▲ +20.7%on this news
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results Conference call to be held today
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results Conference call to be held today, August 8, 2022 at 8:30 AM ET New York, NY, (August 8, 2022) - TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second q
Read more →TGTX▼ -21.8%on this news
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL Company voluntarily withdraws UKONIQ from sale for approved indications of relapsed/refractory MZL and FL Company t
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL Company voluntarily withdraws UKONIQ from sale for approved indications of relapsed/refractory MZL and FL Company to host conference call, Monday, April 18, 2022 at 8:30 AM
Read more →TGTXTG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results Conference call to be held today, Tuesday
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET New York, NY, (March 1, 2022) - TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial res
Read more →TGTX▼ -34.9%on this news
TG Therapeutics Provides Regulatory Update Company to host conference call today, Tuesday
TG Therapeutics Provides Regulatory Update Company to host conference call today, Tuesday, November 30, 2021 at 8:30 AM ET NEW YORK, November 30, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has notif
Read more →TGTX▲ +5.9%on this news
TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results Conference call to be held today, Thursday
TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results Conference call to be held today, Thursday, November 4, 2021 at 8:30 AM ET New York, NY, (November 4, 2021) - TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for
Read more →TGTX▼ -21.6%on this news
TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results Conference call to be held today, Monday
TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results Conference call to be held today, Monday, August 2, 2021 at 8:30 AM ET New York, NY, (August 2, 2021) - TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the
Read more →TGTXTG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results Conference call to be held today, Monday
TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results Conference call to be held today, Monday, May 10, 2021 at 8:30 AM ET New York, NY, (May 10, 2021) - TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first
Read more →TGTXTG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73 rd Annual Meeting Ublituximab demonstrated super
TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse r
Read more →TGTXTG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results Conference call to be held today, Tuesday
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results Conference call to be held today, Tuesday, March 2, 2021 at 8:30 AM ET New York, NY, (March 2, 2021) - TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial resu
Read more →TGTXTG Therapeutics Announces FDA Accelerated Approval of UKONIQ (umbralisib) UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen UKONIQ i
TG Therapeutics Announces FDA Accelerated Approval of UKONIQ (umbralisib) UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen UKONIQ is approved for adult patients with relapsed or refractory
Read more →TGTXTG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis Both studies met their primary endpoint
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis Both studies met their primary endpoint of significantly reducing annualized relapse rate (ARR) (p
Read more →TGTXTG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual Meeting U2 + Venetoclax: 100% ORR at cycle 12 (n=27), including 41% CR rate, and 96% of patients ac
TG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual Meeting U2 + Venetoclax: 100% ORR at cycle 12 (n=27), including 41% CR rate, and 96% of patients achieving undetectable MRD in the peripheral blood and 77% ac
Read more →TGTXTG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results New York, NY, (
TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results New York, NY, (November 9, 2020)- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company developments.
Read more →TGTXTG Therapeutics Highlights Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting UNITY-CLL: U2 significantly improved progression-free survival over obinutuzimab plus chlorambucil
TG Therapeutics Highlights Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting UNITY-CLL: U2 significantly improved progression-free survival over obinutuzimab plus chlorambucil (HR=0.54, p<0.0001) as well as ORR (p<0.001) in patients w
Read more →TGTXTG Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results New York, NY, (
TG Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results New York, NY, (August 10, 2020)- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2020 and recent company developments. M
Read more →TGTXTG Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results New York, NY, (
TG Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results New York, NY, (May 11, 2020) TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ended March 31, 2020 and recent company developments. Michael
Read more →TGTXTG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia UNITY-CLL
TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia UNITY-CLL trial met the primary endpoint of improved progression-free
Read more →TGTXTG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MD New York, NY, (
TG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MD New York, NY, (April 29, 2020) TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the appointment of Sagar Lonial, MD, FACP, to the Company's Board of Directors. Dr. Lonial has extensive expe
Read more →TGTXTG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2019 Financial Results Conference call to be held today, Tuesday
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2019 Financial Results Conference call to be held today, Tuesday, March 3, 2020 at 8:00 AM ET New York, NY, (March 3, 2020) TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial result
Read more →TGTXFORM OF SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “ Agreement” ) is made and entered into as of the 22nd day of December, 2019, by and among TG Therapeutics, Inc., a Delaware co
OF SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this Agreement ) is made and entered into as of the 22nd day of December, 2019, by and among TG Therapeutics, Inc., a Delaware corporation (the Company ) and the purchasers executing the purchaser signature page
Read more →TGTXTG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61 st American Society of Hematology Annual Meeting and Expositio
TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition 100% overall response rate (ORR) in relapsed/refractory
Read more →TGTXTG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results Conference call to be held today, Tuesday
TG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results Conference call to be held today, Tuesday, November 12, 2019 at New York, NY, (November 12, 2019) TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the thi
Read more →TGTXTG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma Follicular lymphoma cohort met the primary e
TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma Follicular lymphoma cohort met the primary endpoint of overall Umbralisib monotherapy appeared to be
Read more →TGTXTG Therapeutics Presents Data for Ublituximab at the 35 th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) New York, NY, (
TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple York, NY, (September 12, 2019) TG Therapeutics, Inc. (NASDAQ: TGTX), today presented the first look at the ULTIMATE I & II Phase 3 trial
Read more →TGTXTG Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results Conference call to be held today, Friday
TG Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results Conference call to be held today, Friday, August 9, 2019 at 8:30 AM New York, NY, (August 9, 2019) TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the s
Read more →TGTXTG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results Conference Call to be held today, Friday
TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results Conference Call to be held today, Friday, May 10, 2019 at 8:00 AM New York, NY, (May 10, 2019) TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first qu
Read more →TGTXTG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71 st Annual Meeting Ublituximab treatment continues to be
TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Ublituximab treatment continues to be well tolerated with a median duration of follow-up of 97.5 weeks
Read more →TGTXTG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting Overall response rate (ORR) of 52% (N=
TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting Overall response rate (ORR) of 52% (N=42), with complete response (CR) rate of 19%, by central
Read more →TGTXTG Therapeutics Announces Positive Outcome from UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with Relapsed/Refractory Marginal Zone Lymphoma Study met the primary endpoint of Overall Response Rate (
TG Therapeutics Announces Positive Outcome from UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with Relapsed/Refractory Marginal Zone Lymphoma Study met the primary endpoint of Overall Response Rate Interim data to be presented in an oral presentation at t
Read more →TGTXTG Therapeutics Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Umbralisib for the Treatment of Marginal Zone Lymphoma Breakthrough Therapy Designation granted based on interim da
TG Therapeutics Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Umbralisib for the Treatment of Marginal Zone Lymphoma Breakthrough Therapy Designation granted based on interim data from the Marginal Zone Lymphoma cohort of the UNITY-
Read more →TGTXTG Therapeutics, Inc. Announces Oral Presentation of Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation at 60 th
TG Therapeutics, Inc. Announces Oral Presentation of Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation at 60th American Society of Hematology Annual Meeting and Exposi
Read more →TGTXTG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2018 Financial Results Investor Conference Call to be Held Today, Friday
TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2018 Financial Results Investor Conference Call to be Held Today, Friday, November 9, 2018 New York, NY, (November 9, 2018) TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for
Read more →TGTXUntitled Document TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the 34 th Congress of ECTRIMS Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 trial ECTRI
TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the 34th Congress of Annualized Relapse Rate (ARR) of 0.07 observed for all patients on ECTRIMS data review conference call to be held today, October 11, 2018, 19:30 CEST/1:30pm ET York, NY
Read more →TGTXTG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Trial Conference call to be held today, Tuesday
TG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Conference call to be held today, Tuesday, September 25, 2018 at YORK, September 25, 2018 - TG Therapeutics (NASDAQ: TGTX) today announced that the independent Data Safety Monitoring Board (DSMB) for the UNITY-CLL P
Read more →TGTXTG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2018 Financial Results Investor Conference Call to be Held Today, Tuesday
Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2018 Financial Results Investor Conference Call to be Held Today, Tuesday, August 7, 2018 New York, NY, (August 7, 2018) TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the
Read more →TGTXTG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy at the 23 rd Congress of the European Hematology Association (EHA) NEW YORK NY (
TG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy at the 23rd Congress of the European Hematology Association (EHA) YORK NY (June 18, 2018) - TG Therapeutics, Inc. (NASDAQ: TGTX), today a
Read more →TGTXTG Therapeutics, Inc. Announces Clinical and Preclinical Data Presentations at the 23 rd Congress of the European Hematology Association NEW YORK, NY (
TG Therapeutics, Inc. Announces Clinical and Preclinical Data Presentations at the 23rd Congress of the European Hematology Association YORK, NY (June 15, 2018) - TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of an integrated analysis of long term sa
Read more →TGTXTG Therapeutics, Inc. Announces Umbralisib Clinical Data Presentation at the 54th Annual Meeting of the American Society of Clinical Oncology CHICAGO, IL (
TG Therapeutics, Inc. Announces Umbralisib Clinical Data Presentation at the 54th Annual Meeting of the American Society of IL (June 4, 2018) - TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated clinical data from its ongoing Phase 2 study evaluating umbralisib (TG
Read more →TGTXTG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2018 Financial Results Investor Conference Call to be Held Today, Tuesday
TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2018 Financial Results Investor Conference Call to be Held Today, Tuesday, May 8, 2018 at York, NY, (May 8, 2018) TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first
Read more →TGTXUntitled Document TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70 th Annual Meeting Data
TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70th Annual Data on now up to 48 patients through 24 weeks confirms previously reported positive re
Read more →TGTXTG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2017 Financial Results and Business Update Investor conference call to be held today, Thursday
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2017 Financial Results and Business Update Investor conference call to be held today, Thursday March 8, 2018 York, NY, (March 8, 2018) TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for t
Read more →TGTXBlueprint TG Therapeutics, Inc. Announces Preclinical & Clinical Data Presentations at the 59 h American Society of Hematology Annual Meeting Clinical presentations continue to underscore safety profile of TGR-1202 as mo
TG Therapeutics, Inc. Announces Preclinical & Clinical Data Presentations at the 59h American Society of Hematology Annual Meeting Clinical presentations continue to underscore safety profile of TGR-1202 as monotherapy and in combination, including in long-term Preclinical a
Read more →TGTXTG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results Investor Conference Call to be Held Today, Wednesday
TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results Investor Conference Call to be Held Today, Wednesday, November 8, York, NY, (November 8, 2017) TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the th
Read more →TGTXBlueprint TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7 th Joint ECTRIMS – ACTRIMS Meeting 100% reduction of T
TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS 100% reduction of T1 Gd-enhancing lesions at week 24 99% median B-cell depletion was observed at week 4 and mai
Read more →TGTXBlueprint TG Therapeutics Provides Update on FDA Meeting for GENUINE Phase 3 Trial Follow-up meeting with FDA expected before year end
TG Therapeutics Provides Update on FDA Meeting for GENUINE Phase 3 Follow-up meeting with FDA expected before year end YORK, October 16, 2017 - TG Therapeutics (NASDAQ: TGTX) announced today that it has met with the U.S. Food and Drug Administration (FDA) regarding the use of
Read more →TGTXBlueprint TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial Enrollment expected to continue until mid-October to allow patients already identified an opportunity to participate in t
TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial Enrollment expected to continue until mid-October to allow patients already identified an opportunity to participate in the YORK, September 5, 2017 -- TG Therapeutics, Inc. (NASDAQ: TGTX)
Read more →TGTXBlueprint TG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial Based on pre-set hurdles of Overall Respons
TG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial Based on pre-set hurdles of Overall Response Rate (ORR) the DSMB recommends continued enrollment in the TGR-1
Read more →TGTXTG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results Investor Conference Call to be Held Today, Wednesday
TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results Investor Conference Call to be Held Today, Wednesday, August 9, York, NY, (August 9, 2017) TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the secon
Read more →TGTXBlueprint TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for a Phase 3 Program of TG-1101 (ublituximab) for Patients with Multiple Sclerosis (MS) Global Phase 3 Program Expected to Com
TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for a Phase 3 Program of TG-1101 (ublituximab) for Patients with Multiple Sclerosis Global Phase 3 Program Expected to Commence Before End of Q3 International Phase 3 Trials Entitled ULTIMATE I
Read more →TGTXBlueprint TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14 th International Conference on Malignant Lymp
TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at International Conference on Malignant Combination of TGR-1202 (umbralisib) plus ibrutinib appears well tolerated with
Read more →TGTXBlueprint TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia at the 53rd Annual Meeting of the American Soc
TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia at the 53rd Annual Meeting of the American Society of Study met its primary endpoint with TG-1101 (ublituximab)
Read more →TGTXBlueprint TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial Contribution of single agents in the combination regimen successfully esta
TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned Independent DSMB in the UNITY-CLL Phase 3 Trial Contribution of single agents in the combination regimen successfully established pursuant to the UNITY-CLL Special Protocol Assessment; DSMB recommends no furt
Read more →TGTXTG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results Investor Conference Call to be Held Today, Friday
TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results Investor Conference Call to be Held Today, Friday, May 5, 2017 at York, NY, (May 5, 2017) TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the first q
Read more →TGTXBlueprint TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting MS patients treated
TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting MS patients treated with TG-1101 exhibited median B-cell depletion TG-1101 was well
Read more →TGTXBlueprint TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update Company solidifies balance sheet with approximately $89M in gross proceeds through the combination of $57.5
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update Company solidifies balance sheet with approximately $89M in gross proceeds through the combination of $57.5M public offering and $31M from at-the-market (ATM) sales facilit
Read more →TGTXUntitled Document TG Therapeutics Announces Positive Topline Data from Phase 3 GENUINE Study of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia (CLL) Study met its primary en
TG Therapeutics Announces Positive Topline Data from Phase 3 GENUINE Study of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia (CLL) Study met its primary endpoint, with TG-1101 (ublituximab) plus ibrutinib increasing Overall Respo
Read more →TGTXTG Therapeutics, Inc. Announces Double & Triple Combination Therapy Data Presentations at the 58 th American Society of Hematology Annual Meeting Combination of TG-1101, TGR-1202 and bendamustine resulted in 71% ORR, inc
Therapeutics, Inc. Announces Double & Triple Combination Therapy Data Presentations at the 58th American Society of Hematology Annual Meeting Combination of TG-1101, TGR-1202 and bendamustine resulted in 71% ORR, including 43% complete response rate, in relapsed or TGR-1202
Read more →TGTXTG Therapeutics, Inc. Announces Preclinical Data Presentations for TGR-1202 at the 58 th American Society of Hematology Annual Meeting Preclinical work may offer rationale for the differentiated activity and safety effec
Therapeutics, Inc. Announces Preclinical Data Presentations for TGR-1202 at the 58th American Society of Hematology Annual Meeting Preclinical work may offer rationale for the differentiated activity and safety effects of TGR-1202 DIEGO, CA (December 5, 2016) - TG Therapeuti
Read more →TGTXTG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2016 Financial Results Investor Conference Call to be Held Today, Monday
TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2016 Financial Investor Conference Call to be Held Today, Monday, November 7, 2016 York, NY, (November 7, 2016) TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the third qu
Read more →TGTXTG Therapeutics, Inc. Amends the GENUINE Phase 3 Clinical Trial to Accelerate Study Completion by Revising Primary Endpoint to Overall Response Rate FDA agrees that Overall Response Rate (ORR) data from revised GENUINE s
Therapeutics, Inc. Amends the GENUINE Phase 3 Clinical Trial to Accelerate Study Completion by Revising Primary Endpoint to Overall FDA agrees that Overall Response Rate (ORR) data from revised GENUINE study can be used to request pre-BLA (Biologics License Application) meeti
Read more →TGTXTG Therapeutics, Inc. Announces Second Quarter 2016 Financial Results and Business Update Investor Conference Call to be Held Today, Monday
TG Therapeutics, Inc. Announces Second Quarter 2016 Financial Results and Business Update Investor Conference Call to be Held Today, Monday, August 8, 2016 at 8:30am ET New York, NY, (August 8, 2016) TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for
Read more →TGTXTG Therapeutics, Inc. Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety Profile and High Response Rates in CLL and NHL in Data Presented at the 52 nd Annual Meeting of the American Society of
TG Therapeutics, Inc. Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety Profile and High Response Rates in CLL and NHL in Data Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology High response rates observed across CL
Read more →TGTXTG Therapeutics, Inc. Announces First Quarter 2016 Financial Results and Business Update Investor Conference Call to be Held Today, Tuesday
TG Therapeutics, Inc. Announces First Quarter 2016 Financial Results and Business Update Investor Conference Call to be Held Today, Tuesday, May 10, New York, NY, (May 10, 2016) - TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the first quarter
Read more →TGTXTG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2015 Financial Results and Business Update Ended 2015 in a Strong Financial Position, With More Than $100 Million in Cash and Investments Investor Conference Ca
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2015 Financial Results and Business Update Ended 2015 in a Strong Financial Position, With More Than $100 Million in Cash and Investments Investor Conference Call to be held Today, Monday March 7, New York, NY, (Mar
Read more →TGTXTG THERAPEUTICS, INC. Common Stock (par value $0.001 per share) Amended and Restated At Market Issuance Sales Agreement
TG THERAPEUTICS, INC. (par value $0.001 per share) Amended and Restated At Market Issuance 1301 Avenue of the Americas New York, New York 10019 FBR Capital Markets & Co. 300 North 17th Street North Arlington, Virginia 22209 Ladies and Gentlemen: TG Therapeutics, Inc. (t
Read more →TGTXTG Therapeutics, Inc. Announces Data Presentations at the 57 th American Society of Hematology Annual Meeting From Ongoing Clinical Studies in Patients with Non-Hodgkins Lymphoma (NHL) and Chronic Lymphocytic Leukemia (C
TG Therapeutics, Inc. Announces Data Presentations at the 57th American Society of Hematology Annual Meeting From Ongoing Clinical Studies in Patients with Non-Hodgkins Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Combination of TG-1101 plus TGR-1202 ("TG-1303") cont
Read more →TGTXTG Therapeutics, Inc. Announces Third Quarter 2015 Financial Results and Business Update Investor Conference Call to be Held Today, Monday
TG Therapeutics, Inc. Announces Third Quarter 2015 Financial Results and Business Update Investor Conference Call to be Held Today, Monday, November 9, 2015 at 8:30am ET New York, NY, (November 9, 2015) - TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial resu
Read more →TGTXTG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for the First Phase 3 Clinical Trial of Its Proprietary Combination Regimen of TG-1101 (ublituximab) in Combination with TGR-1202 for Pat
TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for the First Phase 3 Clinical Trial of Its Proprietary Combination Regimen of TG-1101 (ublituximab) in Combination with TGR-1202 for Patients with Chronic Lymphocytic Leukemia (CLL) Novel Desig
Read more →TGTXTG Therapeutics, Inc. Announces Second Quarter 2015 Financial Results and Business Update Investor Conference Call to be Held Today, Monday
TG Therapeutics, Inc. Announces Second Quarter 2015 Financial Results and Business Update Investor Conference Call to be Held Today, Monday, August 10, 2015 at 8:30am EDT New York, NY, (August 10, 2015) - TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial resu
Read more →TGTXUpdated Results from Phase 2 Clinical Trial of TG-1101 (Ublituximab) in Combination with Ibrutinib Confirms Robust Clinical Activity with a Favorable Safety Profile in Patients With Previously Treated, High-Risk Chronic
Updated Results from Phase 2 Clinical Trial of TG-1101 (Ublituximab) in Combination with Ibrutinib Confirms Robust Clinical Activity with a Favorable Safety Profile in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) 18, 2015 -- TG Therapeutics, I
Read more →TGTXTG Therapeutics, Inc. Announces Presentations of its Proprietary Combination of TG-1101 plus TGR-1202 as well as TGR-1202 as a Single Agent in Ongoing Phase I/Ib Dose Escalation Clinical Studies Triple therapy cohort of
TG Therapeutics, Inc. Announces Presentations of its Proprietary Combination of TG-1101 plus TGR-1202 as well as TGR-1202 as a Single Agent in Ongoing Phase I/Ib Dose Escalation Triple therapy cohort of the combination study to be presented separately as an oral presentation
Read more →TGTXTG Therapeutics, Inc. Announces First Quarter 2015 Financial Results and Business Update Investor Conference Call to be Held Tomorrow, Tuesday
TG Therapeutics, Inc. Announces First Quarter 2015 Financial Results and Business Update Investor Conference Call to be Held Tomorrow, Tuesday, May 5, 2015 at 8:00am EDT New York, NY, (May 4, 2015) - TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results f
Read more →TGTXTG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results and Business Update Investor Conference Call to be held Thursday
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results and Business Update Investor Conference Call to be held Thursday, March 12, 2015 New York, NY, (March 11, 2015) - TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for t
Read more →TGTXTG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors
TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors NEW YORK, NY, December 17, 2014-- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced the appointment of Kenneth Hoberman to the Company's Board of Directors. Mr. Hoberman is currently the
Read more →TGTXInterim Data from Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chro
Interim Data from Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma SAN F
Read more →TGTXTG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update Investor Conference Call to be held
TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update Investor Conference Call to be held November 11, 2014 at New York, NY, (November 10, 2014) - TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative clinical-stage biopharmaceutical company fo
Read more →TGTXTG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination with Imbruvica (ibrutinib) for Patients with Previously Trea
TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination with Imbruvica (ibrutinib) for Patients with Previously Treated Chronic Lymphocytic Leukemia Overall Response Rate (O
Read more →TGTXTG Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Business Update Investor Conference Call to be held
TG Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Business Update Investor Conference Call to be held July 22, 2014 at 8:30am EDT to discuss Second Quarter Financial Results and Preliminary Clinical Data Presented at The Pan Pacific Lymphoma Conference
Read more →TGTXTG Therapeutics' Novel Combination of TG-1101 (Ublituximab) and TGR-1202 Demonstrates Compelling Early Activity and Safety Profile in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia
TG Therapeutics' Novel Combination of TG-1101 (Ublituximab) and TGR-1202 Demonstrates Compelling Early Activity and Safety Profile in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) and Aggressive Lymphomas NEW YORK, July 21, 2014 -- TG Therapeuti
Read more →TGTXTG Therapeutics' TG-1101 (ublituximab) in Combination with Ibrutinib Demonstrates Compelling Clinical Activity and Safety Profile in Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lym
TG Therapeutics' TG-1101 (ublituximab) in Combination with Ibrutinib Demonstrates Compelling Clinical Activity and Safety Profile in Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) New York, NY, (June 13, 2014) - TG Therapeuti
Read more →TGTXTG Therapeutics, Inc. Announces Presentation of Single Agent Data for Both TG-1101 and TGR-1202 in Ongoing Phase I Clinical Studies Highlights from TG-1101 Data Include: 100% of CLL patients achieved a peri
TG Therapeutics, Inc. Announces Presentation of Single Agent Data for Both TG-1101 and TGR-1202 in Ongoing Phase I Clinical Studies Highlights from TG-1101 Data Include: Highlights from TGR-1202 Data Include: NEW YORK, May 30, 2014-- TG Therapeutics, Inc. (Nasdaq:TGTX), an i
Read more →TGTXTG Therapeutics, Inc. Announces First Quarter 2014 Financial Results and Business Update Investor Conference Call to be held Tomorrow, Tuesday
TG Therapeutics, Inc. Announces First Quarter 2014 Financial Results and Business Update Investor Conference Call to be held Tomorrow, Tuesday, May 13, 2014 at 8:30am EDT New York, NY, (May 12, 2014) - TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative clinical-stage biophar
Read more →TGTXTG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results and Business Update Investor Conference Call to be held Thursday
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results and Business Update Investor Conference Call to be held Thursday, March 6, 2014 New York, NY, (March 5, 2014) - TG Therapeutics, Inc. (TGTX), an innovative, clinical-stage biopharmaceutical com
Read more →TGTXTG Therapeutics, Inc. Announces Presentation of Encouraging Clinical Activity of TGR-1202 in an Ongoing Multi-center Phase I Clinical Study All evaluable CLL patients treated with once daily TGR-1202 at 800 mg exhibited
TG Therapeutics, Inc. Announces Presentation of Encouraging Clinical Activity of TGR-1202 in an Ongoing Multi-center Phase I Clinical Study NEW YORK, Dec 9, 2013 - TG Therapeutics, Inc. (Nasdaq: TGTX), an innovative, clinical-stage biopharmaceutical company today announced cl
Read more →TGTXTG Therapeutics, Inc. Comments on Unusual Trading Activity New York, NY, (
TG Therapeutics, Inc. Comments on Unusual Trading Activity New York, NY, (October 28, 2013) - TG Therapeutics, Inc. (NASDAQ:TGTX), reports that in view of the unusual market activity in the Company's stock price, NASDAQ MarketWatch has contacted the company in accordance with
Read more →TGTXPRESENTATION NASDAQ: TGTX September 2013 This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, mad
NASDAQ: TGTX September 2013 This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates", "expects",
Read more →TGTXTG Therapeutics, Inc. Announces Second Quarter 2013 Financial Results and Business Update Investor Conference Call to be held
TG Therapeutics, Inc. Announces Second Quarter 2013 Financial Results and Business Update Investor Conference Call to be held August 2, 2013 at 8:30am New York, NY, (August 1, 2013) - TG Therapeutics, Inc. (TGTX), an innovative clinical-stage biopharmaceutical company focused
Read more →TGTXTG Therapeutics, Inc. Announces Presentation of Interim Results from its Phase I/II Clinical Trial of Single-Agent Ublituximab (TG-1101) in Patients with Rituximab Relapsed/Refractory Non-Hodgkin's Lymphoma TG-1101 Well
TG Therapeutics, Inc. Announces Presentation of Interim Results from its Phase I/II Clinical Trial of Single-Agent Ublituximab (TG-1101) in Patients with Rituximab Relapsed/Refractory Non-Hodgkin's Lymphoma TG-1101 Well Tolerated and Induced 50% Overall Response Rate (5/10)
Read more →TGTXTG Therapeutics, Inc. Approved for Listing on the Nasdaq Capital Market New York, NY, (
TG Therapeutics, Inc. Approved for Listing on the Nasdaq New York, NY, (May 28, 2013) - TG Therapeutics, Inc. (TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of medically important pharmaceutical pro
Read more →TGTXTG Therapeutics, Inc. Announces First Quarter 2013 Financial Results and Business Update Investor Conference Call to be held Tomorrow, Tuesday
TG Therapeutics, Inc. Announces First Quarter 2013 Financial Results and Business Update Investor Conference Call to be held Tomorrow, Tuesday, May 14, 2013 at 8:30am EDT New York, NY, (May 13, 2013) - TG Therapeutics, Inc. (TGTX), an innovative clinical-stage biopharmaceuti
Read more →TGTXTG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results and Business Update Investor Conference Call to be held Tomorrow, Wednesday
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results and Business Update Investor Conference Call to be held Tomorrow, Wednesday, March 13, 2013 at 8:30am EDT New York, NY, (March 12, 2013) - TG Therapeutics, Inc. (TGTX), an innovative, clinical
Read more →TGTXTG Therapeutics, Inc. Announces Poster Presentation Highlights for Ublituximab (TG-1101) and TGR-1202 from the 54 th American Society of Hematology Meeting Dr. Owen O'Connor Presents Early Clinical Data on
TG Therapeutics, Inc. Announces Poster Presentation Highlights for Ublituximab (TG-1101) and TGR-1202 from the 54th American Society of Hematology Meeting Presents Early Clinical Data on the Safety and Efficacy from two Ongoing Phase I Trials of TG-1101 NEW YORK, December 10,
Read more →TGTXTG Therapeutics Announces Exclusive Licensing Agreement with Ildong Pharmaceutical Co., Ltd. for Development and Commercialization of Ublituximab (TGTX-1101) in South Korea and Southeast Asia New York, NY (
TG Therapeutics Announces Exclusive Licensing Agreement with Ildong Pharmaceutical Co., Ltd. for Development and Commercialization of Ublituximab (TGTX-1101) in South Korea and Southeast Asia New York, NY (November 15, 2012)-TG Therapeutics, Inc. (TG Therapeutics) (Ticker:TGTX
Read more →TGTXTG Therapeutics, Inc. Announces Third Quarter 2012 Financial Results and Business Update Investor Conference Call to be held Tomorrow, Friday
TG Therapeutics, Inc. Announces Third Quarter 2012 Financial Results and Business Update Investor Conference Call to be held Tomorrow, Friday, November 9, 2012 at 8:30am EDT New York, NY, (November 8, 2012) - TG Therapeutics, Inc. (TGTX), an innovative, clinical-stage biopha
Read more →TGTXTG THERAPEUTICS AND RHIZEN PHARMACEUTICALS ANNOUNCE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL PI3K DELTA SELECTIVE INHIBITOR, TGR-1202 IND Filing Expected Fourth Quarter 2012 Collaboration and Licen
TG THERAPEUTICS AND RHIZEN PHARMACEUTICALS ANNOUNCE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL PI3K DELTA SELECTIVE INHIBITOR, TGR-1202 IND Filing Expected Fourth Quarter 2012 Collaboration and Licensing Payments Could Exceed $250MM New York, NY (August 1
Read more →TGTXUnassociated Document Manhattan Pharmaceuticals Achieves Ariston Merger Milestone AST-915 Development Program to Continue to Phase 2 NEW YORK, NY JAN 31, 2011 - Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) announced tod
Pharmaceuticals Achieves Ariston Merger Milestone Development Program to Continue to Phase 2 NEW YORK, NY JAN 31, 2011 - Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) announced today that the company's Board of Directors has decided to continue development of AST-915, an oral
Read more →TGTXManhattan Pharmaceuticals Announces Entry into Settlement and Release Agreement with Nordic Biotech Settlement and Release Agreement Resolves Disagreements Concerning H Pharmaceuticals Joint Venture, Provides Non-dilutiv
Pharmaceuticals Announces Entry into Settlement and Release Agreement with and Release Agreement Resolves Disagreements Concerning H Pharmaceuticals Joint Venture, Provides Non-dilutive Funding, and Improves Capital NEW YORK, NY JAN 10, 2011 - Manhattan Pharmaceuticals, Inc.
Read more →TGTXManhattan Pharmaceuticals Awarded $245K Grant under the U.S. Qualified Therapeutic Discovery Project Credit Program NEW YORK, NY NOV 8, 2010 - Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) announced today that it has bee
Pharmaceuticals Awarded $245K Grant under the U.S. Qualified Therapeutic Discovery Project Credit Program NEW YORK, NY NOV 8, 2010 - Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) announced today that it has been awarded $244,279 in funding under the U.S. Government's Qualifyi
Read more →TGTXManhattan Pharmaceuticals Announces Private Placement Final Close at $3.0 Million NEW YORK, NY APRIL 14, 2010 - Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) today announced the final close of its private placement in wh
Pharmaceuticals Announces Private Placement Final Close at $3.0 NEW YORK, NY APRIL 14, 2010 - Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) today announced the final close of its private placement in which it sold approximately 121 units, including the conversion of approxima
Read more →TGTXManhattan Pharmaceuticals Completes Merger Transaction with Ariston Pharmaceuticals NEW YORK, NY MAR 11, 2010 - Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) today announced it has entered into a definitive agreement and
Pharmaceuticals Completes Merger Transaction with Ariston NEW YORK, NY MAR 11, 2010 - Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) today announced it has entered into a definitive agreement and plan of merger and completed the merger transaction with Ariston Pharmaceuticals,
Read more →TGTXManhattan Pharmaceuticals Completes $2.5 Million Financing NEW YORK, NY MAR 4, 2010 - Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) today announced the private placement of $2,547,500 of its common stock and warrants to
Pharmaceuticals Completes $2.5 Million Financing NEW YORK, NY MAR 4, 2010 - Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) today announced the private placement of $2,547,500 of its common stock and warrants to accredited investors. The Company intends to complete the previous
Read more →TGTXManhattan Pharmaceuticals Provides Corporate Update on Hedrin and Management Restructuring NEW YORK, NY JUN 18, 2009 - Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) today provided an update on its ongoing development pro
Pharmaceuticals Provides Corporate Update on Hedrin and Management NEW YORK, NY JUN 18, 2009 - Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) today provided an update on its ongoing development programs. The Company also announced it has initiated a management restructuring th
Read more →TGTXManhattan Pharmaceuticals Completes $1 Million Financing NEW YORK, NY NOV 25, 2008 - Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) today announced that it has completed the first closing of a private placement of secured
Pharmaceuticals Completes $1 Million Financing YORK, NY NOV 25, 2008 Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) today announced that it has completed the first closing of a private placement of secured debt and warrants to purchase shares of its common stock. Pursuant to t
Read more →TGTXManhattan Pharmaceuticals Announces Amendment of Joint Venture Deal with Nordic Biotech Company to Receive $1.0 Million in Cash and $1.25 Million in Equity NEW YORK, NY JUN 12, 2008 - Manhattan Pharmaceuticals, Inc. (OTC
Pharmaceuticals Announces Amendment of Joint Venture Deal with Nordic to Receive $1.0 Million in Cash and $1.25 Million in Equity YORK, NY JUN 12, 2008 Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) today announced that the FDA novel, non-insecticide treatment for pediculosis
Read more →TGTXManhattan Pharmaceuticals to Voluntarily Withdraw its American Stock Exchange Common Stock Listing Company to Move to Complete Joint Venture Agreement with Nordic Biotech NEW YORK, NY FEB 22, 2008 - Manhattan Pharmaceuti
Pharmaceuticals to Voluntarily Withdraw its Stock Exchange Common Stock Listing to Move to Complete Joint Venture Agreement with Nordic Biotech YORK, NY FEB 22, 2008 Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that it has formally notified the American Stock
Read more →TGTXManhattan Pharmaceuticals Announces Joint Venture With Nordic Biotech for Lead Product Hedrin Companies Sign $9.65M Deal to Develop and Commercialize Hedrin, a Next Generation Treatment for Pediculitis (Head Lice)
Pharmaceuticals Announces Joint Venture With Nordic Biotech for Lead Product Sign $9.65M Deal to Develop and Commercialize Hedrin, a Next Generation Treatment for Pediculitis (Head Lice) YORK, Feb 5, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, I
Read more →TGTXManhattan Pharmaceuticals Names Mary C. Spellman, M.D. as Head of Dermatology and Drug Development Alan Harris Departs to Pursue Other Business Opportunities NEW YORK, NY DEC 27, 2007 - Manhattan Pharmaceuticals, Inc. (A
Pharmaceuticals Names Mary C. Spellman, as Head of Dermatology and Drug Development Harris Departs to Pursue Other Business Opportunities YORK, NY DEC 27, 2007 Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced the appointment Mary C. Spellman, M.D. as its consultan
Read more →TGTXPipeline Update
Pipeline Update
Read more →TGTXManhattan Receives Notification from AMEX of Non-compliance with Certain Listing Standards NEW YORK, NY SEPT 21, 2007 - Manhattan Pharmaceuticals, Inc. (AMEX: MHA) received notice from the American Stock Exchange (AMEX)
Receives Notification from AMEX of with Certain Listing Standards YORK, NY SEPT 21, 2007 Manhattan Pharmaceuticals, Inc. (AMEX: MHA) received notice from the American Stock Exchange (AMEX) dated September 18, 2007 indicating that the company not in compliance with Section 10
Read more →TGTXNews From: Contact: Douglas Abel President & Chief Executive Officer Manhattan Pharmaceuticals, Inc. 212.582.3950 Michelle Carroll Corporate Communications Manhattan Pharmaceuticals, Inc. 212.582.3950 Manhattan Pharmaceu
Pharmaceuticals Announces Results of 2a Studies for Oral Oleoyl-estrone YORK, NY JULY 9, 2007 Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced results of the company's two Phase 2a clinical trials of oral Oleoyl-estrone (OE). The results of both randomized, double
Read more →TGTXManhattan Pharmaceuticals Acquires Hedrin for the Treatment of Head Lice NEW YORK, JUNE 27 -- Manhattan Pharmaceuticals, Inc. (Amex: MHA - News) today announced that it has acquired exclusive, North American rights to de
Pharmaceuticals Acquires Hedrin the Treatment of Head Lice JUNE 27 -- Manhattan Pharmaceuticals, Inc. (Amex: MHA - News) today announced that it has acquired exclusive, North American rights to develop and commercialize Hedrin , a novel, non-insecticide product candidate for
Read more →TGTXManhattan Pharmaceuticals Announces License Agreement and Expanded Pipeline Company Acquires Two New Clinical-Stage Drug Candidates NEW YORK, APRIL 4 /PRNewswire-FirstCall/ - Manhattan Pharmaceuticals, Inc. (Amex: MHA -
Pharmaceuticals Announces License Agreement and Expanded Acquires Two New Clinical-Stage Drug Candidates APRIL 4 /PRNewswire-FirstCall/ - Manhattan Pharmaceuticals, Inc. (Amex: announced that it has acquired exclusive, North American rights to develop commercialize two novel
Read more →TGTXMichael G. McGuinness Chief Financial Officer Manhattan Pharmaceuticals, Inc. 212/582-3950 Thomas Redington Redington, Inc. 203/222-7399 212/926-1733 AMEX Accepts Manhattan Pharmaceuticals' Plan to Regain Compli
Accepts Manhattan Pharmaceuticals' Plan to Compliance with Continued Listing Standards YORK, NY MAR 27, 2007 Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that the American Stock Exchange (AMEX) has accepted the Company's plan to regain compliance continued lis
Read more →TGTXManhattan Receives Notification from AMEX of Non-compliance of Certain Listing Standards NEW YORK, NY JAN 12, 2007 - Manhattan Pharmaceuticals, Inc. (AMEX: MHA) previously reported in its Form 10-QSB for the quarter ende
Receives Notification from AMEX of of Certain Listing Standards YORK, NY JAN 12, 2007 Manhattan Pharmaceuticals, Inc. (AMEX: MHA) previously reported in its Form 10-QSB for the quarter ended September 30, 2006 that at September 30, 2006, company did not meet one of the Ameri
Read more →TGTXSource: Manhattan Pharmaceuticals, Inc. Manhattan Pharmaceuticals Reports Update on Clinical Development Programs
Pharmaceuticals Reports Update on Clinical Development April 28, 2006 (PRIMEZONE) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA announced the following update regarding the development status of oral Oleoyl-estrone for obesity and topical PTH (1-34) for psoriasis. IIa protocol
Read more →TGTXDr. Harris is a Fellow of the American College of Physicians, the Royal College of Physicians (UK), and the American College of Clinical Pharmacology. He serves as trustee of the Hospital for Joint Diseases-NYU Medical C
[Letterhead of Manhattan Pharmaceuticals, Inc.] Contact: Nicholas J. Rossettos, CPA Thomas Redington Chief Financial Officer Redington, Inc. Manhattan Pharmaceuticals, Inc. 203/222-7399 212/582 3950 212/926-1733 MANHATTAN PHARMACEUTICALS NAMES ALAN HARRIS CHIEF MEDICAL OFFI
Read more →TGTXSource: Manhattan Pharmaceuticals, Inc. Manhattan Pharmaceuticals Raises $11.9 Million in Private Placement Tuesday August 30, 9:30 am
Pharmaceuticals Raises $11.9 Million in Private Placement August 30, 9:30 am ET Aug. 30, 2005 (PRIMEZONE) -- Manhattan Pharmaceuticals, Inc. (OTC completed a private placement of common stock and warrants to institutional accredited investors resulting in gross proceeds of ap
Read more →TGTXManhattan Pharmaceuticals Acquires Tarpan Therapeutics Monday April 4, 8:30 am ET Douglas Abel Becomes Chief Executive Officer Development Portfolio Now Includes Therapeutics for Psoriasis, Obesity and a Lingual Spray fo
Pharmaceuticals Acquires Tarpan Therapeutics Abel Becomes Chief Executive Officer Portfolio Now Includes Therapeutics for Psoriasis, Obesity and Lingual Spray for Pre-Procedural Sedation YORK--(BUSINESS WIRE)--April 4, 2005-- Manhattan Pharmaceuticals, Inc. ("Manhattan" OTCB
Read more →TGTXSource: Manhattan Pharmaceuticals, Inc. Manhattan Pharmaceuticals, Inc. to Merge with Tarpan Therapeutics, Inc. Wednesday January 5, 8:30 am ET Merger Diversifies Portfolio of Therapeutic Compounds, Adds Phase I/II Produ
Manhattan Pharmaceuticals, Inc. to Merge with Tarpan Therapeutics, Inc. Wednesday January 5, 8:30 am ET Merger Diversifies Portfolio of Therapeutic Compounds, Adds Phase I/II Product Candidate and Augments Management Team NEW YORK--(BUSINESS WIRE)--Jan. 5, 2005-- Manhattan Pha
Read more →Competitive Position
How TGTX ranks across every disease it competes inCompetitive Position is a premium feature
See how TGTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial